企业档案
易推广认证,请放心拨打
上海复祥生物科技有限公司
会员类型:会员
已获得易推广信誉 等级评定
(0 -40)基础信誉积累,可浏览访问
(41-90)良好信誉积累,可接洽商谈
(91+ )优质信誉积累,可持续信赖
易推广会员:13年
最后认证时间:
注册号:**** 【已认证】
法人代表:【已认证】
企业类型:生产商【已认证】
注册资金:人民币万【已认证】
产品数:1133
参观次数:767388
手机商铺二维码
产品展示更多>>
当前位置: 易推广 > 生物试剂/抗体/细胞 > 生物制剂 > 其他 > 上海复祥生物科技有限公司 > 产品展示 > 细胞库 > 人肿瘤、癌细胞 > K-562 人慢性髓原白血病细胞
K-562 人慢性髓原白血病细胞
点击次数:361  发布时间:2011/11/25[更新时间:2024/11/14 14:28:39]
- 型 号:
- 价 格:面议
- 所在地点:美洲
- 产品完善度:
| 产品简介
K-562 人慢性髓原白血病细胞
ATCC® Number: CCL-243™
Designations: K-562
Depositors: HT Holden
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: suspension
Organism: Homo sapiens (human)
Morphology: lymphoblast
Source: Organ: bone marrow
Disease: chronic myelogenous leukemia (CML)
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Applications: transfection host (Nucleofection technology from Lonza)
Tumorigenic: Yes
Reverse Transcript: negative
Antigen Expression: CD7 (25%)
DNA Profile (STR): Amelogenin: X
CSF1PO: 9,10
D13S317: 8
D16S539: 11,12
D5S818: 11,12
D7S820: 9,11
THO1: 9.3
TPOX: 8,9
vWA: 16
Cytogenetic Analysis: The stemline chromosome number is triploid with the 2S component occurring at 4.2%. Fifteen markers (M1 and M(15)) occurred in nearly all S metaphases. Spontaneous non-specific dicentrics occurred, but rarely. Unstable markers were also rarely seen. The X was disomic, and N9 was nullisomic.
Isoenzymes: AK-1, 1
ES-D, 1
G6PD, B
GLO-I, 2
Me-2, 0
PGM1, 0
PGM3, 1
Age: 53 years
Gender: female
Comments: The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises. [22609]
The cell population has been characterized as highly undifferentiated and of the granulocytic series. [26059]
Studies conducted by Anderson, et al., on the surface membrane properties led to the conclusion that the K-562 was a human erythroleukemia line. [26060]
The K-562 cell line has attained widespread use as a highly sensitive in vitro target for the natural killer assay. [48829] [1101] [48830]
See Pross, et al. for a detailed analysis of the in vitro assay of NK cells including the mathematics of quantitation of NK cell activity. [48833]
K-562 blasts are multipotential, hematopoietic malignant cells that spontaneously differentiate into recognizable progenitors of the erythrocytic, granulocytic and monocytic series. [26061]
The effect of inducers on sublines derived from the original K-562 cell line have been reviewed by Koeffler and Golde. [867]
Cultures from the ATCC stock have been shown to exhibit this sensitivity for assessing human natural killer activity.
Karyological studies on various K-562 sublines have been classified into three groups (A,B,C) by Dimery, et al. [26063]
The strain obtained by the ATCC most closely resembles the B population. Occurrence of the Philadelphia chromosome, however, was of much lower frequency; detected in 15 metaphases examined.
The line is EBNA negative.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by the addition or replacement of fresh medium. Start new cultures at 1 X 10 exp5 viable cells/ml. Subculture at 1 X 10 exp6 cells/ml.
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor temperature
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2005
recommended serum:ATCC 30-2020
purified DNA:ATCC CCL-243D
purified RNA:ATCC CCL-243R
References: 867: Koeffler HP, Golde DW. Human myeloid leukemia cell lines: a review. Blood 56: 344-350, 1980. PubMed: 6996765
1101: Ortaldo JR, et al. Specificity of natural cytotoxic reactivity of normal human lymphocytes against a myeloid leukemia cell line. J. Natl. Cancer Inst. 59: 77-82, 1977. PubMed: 69036
22609: Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 45: 321-334, 1975. PubMed: 163658
26059: Lozzio BB, Lozzio CB. Properties and usefulness of the original K-562 human myelogenous leukemia cell line. Leuk. Res. 3: 363-370, 1979. PubMed: 95026
26060: Andersson LC, et al. K562--a human erythroleukemic cell line. Int. J. Cancer 23: 143-147, 1979. PubMed: 367973
26061: Lozzio BB, et al. A multipotential leukemia cell line (K-562) of human origin. Proc. Soc. Exp. Biol. Med. 166: 546-550, 1981. PubMed: 7194480
26063: Dimery IW, et al. Variation amongst K562 cell cultures. Exp. Hematol. 11: 601-610, 1983. PubMed: 6576909
32357: Chan YJ, et al. Two distinct upstream regulatory domains containing multicopy cellular transcription factor binding sites provide basal repression and inducible enhancer characteristics to the immediate-